139 related articles for article (PubMed ID: 15803005)
1. High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer.
Chaudhary UB; Damon LE; Rugo HS; Linker CA; Navarro W; Small EJ
Am J Clin Oncol; 2005 Apr; 28(2):130-7. PubMed ID: 15803005
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
[TBL] [Abstract][Full Text] [Related]
3. High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group.
Siegert W; Beyer J; Strohscheer I; Baurmann H; Oettle H; Zingsem J; Zimmermann R; Bokemeyer C; Schmoll HJ; Huhn D
J Clin Oncol; 1994 Jun; 12(6):1223-31. PubMed ID: 7911158
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell cancer.
Margolin KA; Doroshow JH; Frankel P; Chow W; Leong LA; Lim D; McNamara M; Morgan RJ; Shibata S; Somlo G; Twardowski P; Yen Y; Kogut N; Schriber J; Alvarnas J; Stalter S
Biol Blood Marrow Transplant; 2005 Nov; 11(11):903-11. PubMed ID: 16275593
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and usefulness of high-dose chemotherapy (high-dose ifosfamide, carboplatin and etoposide) combined with peripheral blood stem cell transplantation for male germ cell tumor: a single-institute experience.
Hara I; Miyake H; Yamada Y; Yamanaka K; Furukawa J; Kumano M; Takenaka A; Fujisawa M
Anticancer Drugs; 2006 Oct; 17(9):1057-66. PubMed ID: 17001179
[TBL] [Abstract][Full Text] [Related]
6. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol.
Nichols CR; Andersen J; Lazarus HM; Fisher H; Greer J; Stadtmauer EA; Loehrer PJ; Trump DL
J Clin Oncol; 1992 Apr; 10(4):558-63. PubMed ID: 1312584
[TBL] [Abstract][Full Text] [Related]
7. Dose-intensive chemotherapy in refractory germ cell cancer--a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation.
Nichols CR; Tricot G; Williams SD; van Besien K; Loehrer PJ; Roth BJ; Akard L; Hoffman R; Goulet R; Wolff SN
J Clin Oncol; 1989 Jul; 7(7):932-9. PubMed ID: 2544687
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors.
Motzer RJ; Mazumdar M; Gulati SC; Bajorin DF; Lyn P; Vlamis V; Bosl GJ
J Natl Cancer Inst; 1993 Nov; 85(22):1828-35. PubMed ID: 7693955
[TBL] [Abstract][Full Text] [Related]
9. A phase I dose escalation study of high-dose thiotepa, melphalan and carboplatin (TMCb) followed by autologous peripheral blood stem cell transplantation (PBSCT) in patients with solid tumors and hematologic malignancies.
Demirer T; Ilhan O; Mandel NM; Arat M; Günel N; Celebi H; Ustün C; Akan H; Demirer S; Aydintuğ S; Uysal A; Koç H
Bone Marrow Transplant; 2000 Apr; 25(7):697-703. PubMed ID: 10745253
[TBL] [Abstract][Full Text] [Related]
10. Treatment of germ cell cancer with two cycles of high-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.
Margolin K; Doroshow JH; Ahn C; Hamasaki V; Leong L; Morgan R; Raschko J; Shibata S; Somlo G; Tetef M
J Clin Oncol; 1996 Oct; 14(10):2631-7. PubMed ID: 8874321
[TBL] [Abstract][Full Text] [Related]
11. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer.
Rick O; Bokemeyer C; Beyer J; Hartmann JT; Schwella N; Kingreen D; Neureither S; Metzner B; Casper J; Wandt H; Hartmann F; Schmoll HJ; Derigs G; Gerl A; Berdel WE; Kanz L; Siegert W
J Clin Oncol; 2001 Jan; 19(1):81-8. PubMed ID: 11134198
[TBL] [Abstract][Full Text] [Related]
12. Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities.
Fields KK; Elfenbein GJ; Perkins JB; Hiemenz JW; Janssen WE; Zorsky PE; Ballester OF; Kronish LE; Foody MC
Semin Oncol; 1993 Oct; 20(5 Suppl 6):59-66. PubMed ID: 8211217
[TBL] [Abstract][Full Text] [Related]
13. Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas.
Mabed M; Al-Kgodary T
Bone Marrow Transplant; 2006 Apr; 37(8):739-43. PubMed ID: 16501587
[TBL] [Abstract][Full Text] [Related]
14. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
[TBL] [Abstract][Full Text] [Related]
15. [High dose chemotherapy with thiotepa, carboplatin, VP16 and autologous stem cell transplantation in treatment of malignant brain tumors with poor prognosis. Results of a mono-center pilot study].
Fleischhack G; Pöpping K; Hasan C; Utsch B; Jüttner J; Bode U
Klin Padiatr; 1998; 210(4):248-55. PubMed ID: 9743961
[TBL] [Abstract][Full Text] [Related]
16. Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors.
Broun ER; Nichols CR; Mandanas R; Salzman D; Turns M; Hromas R; Cornetta K; Einhorn LH
Bone Marrow Transplant; 1995 Sep; 16(3):353-8. PubMed ID: 8535306
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue.
Broun ER; Nichols CR; Kneebone P; Williams SD; Loehrer PJ; Einhorn LH; Tricot GJ
Ann Intern Med; 1992 Jul; 117(2):124-8. PubMed ID: 1318648
[TBL] [Abstract][Full Text] [Related]
18. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma.
Fontelonga A; Kelly AJ; MacKintosh FR; Hall S; Monroe P; Wilson GS; Shaft D; Ruthven A; Ascensao JL
Bone Marrow Transplant; 1997 May; 19(10):983-8. PubMed ID: 9169642
[TBL] [Abstract][Full Text] [Related]
19. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study].
Shi Y; Pan F; Han X
Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500
[TBL] [Abstract][Full Text] [Related]
20. Phase II Trial Assessing the Ability of Neoadjuvant Chemotherapy With or Without Second-Look Surgery to Eliminate Measurable Disease for Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study.
Goldman S; Bouffet E; Fisher PG; Allen JC; Robertson PL; Chuba PJ; Donahue B; Kretschmar CS; Zhou T; Buxton AB; Pollack IF
J Clin Oncol; 2015 Aug; 33(22):2464-71. PubMed ID: 26101244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
